Key result
Iodopovidone pleurodesis achieved a complete response in 86.5% of patients with pleural effusion and 92.6% with pneumothorax, with no recurrences during follow-up.
Why the study?
Does iodopovidone pleurodesis through tube thoracostomy prevent recurrence in patients with recurrent pleural effusions and pneumothorax?
Observational (n=64)
Does iodopovidone pleurodesis through tube thoracostomy prevent recurrence in patients with recurrent pleural effusions and pneumothorax?
Iodopovidone is an effective, safe, inexpensive, and readily available agent for chemical pleurodesis in patients with recurrent pleural effusions and pneumothorax.
Iodopovidone pleurodesis showed high success without recurrence in this cohort; leaves open confirmation versus alternatives in randomized trials.
OBJECTIVE: To evaluate the efficacy and safety of iodopovidone as an agent for pleurodesis through tube thoracostomy in patients with recurrent pleural effusions and pneumothorax. METHODS: This was a prospective study in which pleurodesis was performed with a solution of 20 mL 10% iodopovidone and 80 mL normal saline solution infused through a tube thoracostomy and left in the pleural cavity for 4 h. RESULTS: A total of 64 patients (34 men) with a mean (+/-SD) age of 47.1 +/- 15.4 years were included. There were 37 cases of pleural effusion and 27 of pneumothorax. A complete response (neither reaccumulation of fluid nor recurrence of pneumothorax) was obtained in 32 (86.5%) patients with pleural effusion and 25 (92.6%) patients with pneumothorax. A second procedure (i.e. repeated pleurodesis) was attempted successfully in four patients in the pleural effusion group. All patients experienced chest pain to a varying degree as recorded on a Visual Analogue Scale (median 50.5, range 10-95). Seven patients developed fever and one immunocompromised patient developed empyema following the procedure. There were no recurrences at a median follow up of 5 months (range 3-15 months) in the pleural effusion group, and 13 months (range 6-24 months) in the pneumothorax group. CONCLUSIONS: Iodopovidone can be used as an effective and safe agent for (chemical) pleurodesis (through tube thoracostomy), which is inexpensive and readily available.
No takes yet. Share an insight, caveat, or question.
Agarwal et al. (2006) conducted an observational in recurrent pleural effusions and pneumothorax (n=64). Iodopovidone pleurodesis was evaluated on Complete response (neither reaccumulation of fluid nor recurrence of pneumothorax). Iodopovidone pleurodesis achieved a complete response in 86.5% of patients with pleural effusion and 92.6% with pneumothorax, with no recurrences during follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: